Predictive factors and opioid responsiveness in cancer pain

European Journal of Cancer

Volumn 34, Issue 5, 1998, Pages 627-631

  Mercadante, S ^a  

^a Buccheri La Ferla Fatebenefratelli Hospital   (Italy)

Author keywords

Cancer pain; Incident pain; Neuropathic; Opioid responsiveness; Tolerance

Indexed keywords

ANALGESIC AGENT; MORPHINE;

CANCER PAIN; HUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0032055896     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10053-3     Document Type: Article

References (52)

1. Mercadante S, Dardanoni G, Salvaggio L, Armata MG, Agnello A. Monitoring of opioid therapy in advanced cancer pain patients. J Pain Symptom Manage 1997, 13, 204-212.
2. Banning A, Sjogren P, Henriksen H. Treatment outcome in a multidisciplinary cancer pain clinic. Pain 1991, 47, 129-134.
3. Bruera E, MacMillan D, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: preliminary report. Pain 1989,37, 203-210.
4. Mercadante S, Maddaloni S, Roccella S, Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain 1992, 50, 151-155.
5. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990, 43, 273-286.
6. Collin E, Poulain P, Gauvain-Piquard A, Petit G, PichardLeandri E. Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment? Pain 1993, 55, 319-326.
7. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997, 69, 1-18.
8. Portenoy RK. Tolerance to opioid analgesics: clinical aspects. Cancer Surveys 1995, 21, 49-65.
9. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986, 25, 171-186.
10. Fainsinger RL, Bruera E. Is this opioid analgesic tolerance? J Pain Symptom Manage 1995, 10, 573-577.
11. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988, 33, 11-23.
12. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ. Morphine responsiveness of chronic pain: double blind randomized crossover study with patient-controlled analgesia. Lancet 1992, 339, 1367-1371.
13. Ashby MA, Fleming BG, Brooksbank M, et al. Description of a mechanistic approach to pain management in advanced cancer. Preliminary report. Pain 1992, 51, 153-161.
14. Vecht CJ. Nociceptive nerve pain and neuropathic pain. Pain 1989,39, 243-244.
15. Bruera E, MacMillian K, Kuehn N, Miller MJ. Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain 1992, 49, 311-314.
16. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990, 41, 273-281.
17. Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990, 5, 83-93.
18. Hanks GW, Portenoy RK, MacDonald N, O'Neill W. Difficult pain problems. In Doyle D, Hanks GW and MacDonald N, eds. Oxford Textbook of Palliative Medicine. Oxford, Oxford Medical Publications, 1993, 257-274.
19. Mercadante S. What is the definition of breakthrough pain? Pain 1991,45, 107.
20. Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain. Cancer 1995, 76, 1288-1293.
21. Saeki S, Yaksh TL. Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy. Anesth Analg 1993, 77, 265-274.
22. Dirig DM, Yaksh TL. Differential right shifts in the doseresponse curve for intrathecal morphine and sufentanil as a function of stimulus intensity. Pain 1995, 62, 321-328.
23. Stouz ND de, Bruera E, Suarez-Alazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995, 10, 378-384.
24. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of active metabolite morphine6-glucuronide. Clin Pharmacol Ther 1990, 47, 12-19.
25. Smith GD, Smith MT. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain 1995, 62, 51-60.
26. Werz MA, MacDonald RL. Opiate alkaloids antagonize postsynaptic glycine and GABA responses: correlation with convulsant action. Brain Res 1982, 236, 107-119.
27. Morley JS, Miles JB, BowsherD. Paradoxical pain. Lancet 1992, 340, 1045.
28. Sjogren P, Dragsted L, Christensen CB. Myoclonic spasm during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993, 37, 780-782.
29. Sjogren P, Jonsson T, Jensen NH, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993, 55, 93-97.
30. Gourcke CR, Hackett LP, Ilett KF. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain 1994, 56, 145-149.
31. Samuelsson H, Hedner T, Venn R, Michalkiewicz A. CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine. Pain 1993, 51, 179-185.
32. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioidrelated side effects: a survey in cancer patients. Pain 1995, 61, 47-54.
33. Zaw-Tun N, Bruera E. Active metabolites of morphine. J Palliat Care 1992, 8, 48-50.
34. Portenoy RK, Khan E, Layman M, et al. Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology 1991,41, 1457-1461.
35. D'Honneur G, Gilton A, Sandouk P, Scherrman JM, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology 1994, 81, 87-93.
36. Calleja MA, Childs D, Venn RF, et al. Persistently increased morphine-6-glucuronide concentrations. Br J Anesth 1990, 64, 649.
37. Glare PA, Walsh TD, Pippenger CE. Normorphine, a neurotoxic metabolite? Lancet 1990, 335, 725-728.
38. Inturrisi CE, Umans JG. Pethidine and its active metabolite norpethidine. Clin Anesthesiol 1983, 1, 123-128.
39. Babul N, Darke AC. Putative role of hydromorphone metabolites in myoclonus. Pain 1992, 51, 260-261.
40. Peterson GM, Randall CTG, Peterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990, 38, 121-124.
41. Vainio A, Tigerstedt I. Opioid treatment for radiation cancer pain: oral vs. epidural techniques. Acta Anesthesiol Scand 1988, 32, 179-185.
42. Sjogren P, Banning A. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain 1989, 39, 5-11.
43. Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 1996, 67, 443-449.
44. Samuelsson H, Hedner T. Pain characterization in cancer patients and the analgesic response to epidural morphine. Pain 1991,46,3-8.
45. Unruh AM. Gender variations in clinical pain experience. Pain 1996,65, 123-167.
46. Coyle N, Breitbart W, Weaver S, Portenoy RK. Delirium as a contributing factor to 'crescendo' pain: three case reports. J Pain Symptom Manage 1994, 9, 44-47.
47. Serlin RC, Mendoza TR, Nakamura Y. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995, 61, 277-284.
48. Greenwald HP. Interethnic differences in pain perceptions. Pain 1991,44, 157-163.
49. Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Pain 1982, 50, 1913-1918.
50. Bruera E, MacDonald RN. Intractable pain in patients with advanced head and neck tumors: a possible role of local infection. Cancer Treat Rep 1986, 70, 691-692.
51. Coyle N, Portenoy RK. Infection as a cause of rapidly increasing pain in cancer patients. J Pain Symptom Manage 1991, 6, 266269.
52. Mackey JR, Birchall I, MacDonald N. Occult infection as a cause of hip pain in a patient with metastatic breast cancer. 1995, 10, 569-572.